These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34028703)

  • 1. Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study.
    Wells AF; Jia B; Xie L; Valenzuela GJ; Keystone EC; Li Z; Quebe AK; Griffing K; Otawa S; Haraoui B
    Rheumatol Ther; 2021 Jun; 8(2):987-1001. PubMed ID: 34028703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy Of Baricitinib in Patients With Moderate-To-Severe Rheumatoid Arthritis Up to 6.5 Years Of Treatment: Results Of A Long-Term Study.
    Caporali R; Taylor PC; Aletaha D; Sanmartí R; Takeuchi T; Mo D; Haladyj E; Bello N; Zaremba-Pechmann L; Fang Y; Dougados M
    Rheumatology (Oxford); 2024 Jan; ():. PubMed ID: 38258434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study.
    Smolen JS; Xie L; Jia B; Taylor PC; Burmester G; Tanaka Y; Elias A; Cardoso A; Ortmann R; Walls C; Dougados M
    Rheumatology (Oxford); 2021 May; 60(5):2256-2266. PubMed ID: 33200220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials.
    Sholter D; Wu J; Jia B; Zhang H; Griffing K; Birt J; Reis PJS; Liu H; Bingham CO
    Rheumatol Ther; 2022 Apr; 9(2):541-553. PubMed ID: 34990002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.
    Rubbert-Roth A; Kato K; Haraoui B; Rischmueller M; Liu Y; Khan N; Camp HS; Xavier RM
    Rheumatol Ther; 2024 Jul; ():. PubMed ID: 39031276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis.
    Wells AF; Greenwald M; Bradley JD; Alam J; Arora V; Kartman CE
    Rheumatol Ther; 2018 Jun; 5(1):43-55. PubMed ID: 29680881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis.
    Emery P; Tanaka Y; Cardillo T; Schlichting D; Rooney T; Beattie S; Helt C; Smolen JS
    Arthritis Res Ther; 2020 May; 22(1):115. PubMed ID: 32414425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
    Dougados M; van der Heijde D; Chen YC; Greenwald M; Drescher E; Liu J; Beattie S; Witt S; de la Torre I; Gaich C; Rooney T; Schlichting D; de Bono S; Emery P
    Ann Rheum Dis; 2017 Jan; 76(1):88-95. PubMed ID: 27689735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND.
    van der Heijde D; Kartman CE; Xie L; Beattie S; Schlichting D; Mo D; Durez P; Tanaka Y; Fleischmann R
    J Rheumatol; 2022 Feb; 49(2):133-141. PubMed ID: 34526397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
    Smolen JS; Kremer JM; Gaich CL; DeLozier AM; Schlichting DE; Xie L; Stoykov I; Rooney T; Bird P; Sánchez Bursón JM; Genovese MC; Combe B
    Ann Rheum Dis; 2017 Apr; 76(4):694-700. PubMed ID: 27799159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.
    Kremer JM; Schiff M; Muram D; Zhong J; Alam J; Genovese MC
    RMD Open; 2018; 4(1):e000581. PubMed ID: 29479473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib.
    Pope JE; Lee YC; Curtis JR; Mo D; Xie L; Dickson CL; Schlichting DE; Cardoso A; Simon LS; Taylor PC
    ACR Open Rheumatol; 2022 Mar; 4(3):254-258. PubMed ID: 34913611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
    Smolen JS; Genovese MC; Takeuchi T; Hyslop DL; Macias WL; Rooney T; Chen L; Dickson CL; Riddle Camp J; Cardillo TE; Ishii T; Winthrop KL
    J Rheumatol; 2019 Jan; 46(1):7-18. PubMed ID: 30219772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baricitinib in Patients with Refractory Rheumatoid Arthritis.
    Genovese MC; Kremer J; Zamani O; Ludivico C; Krogulec M; Xie L; Beattie SD; Koch AE; Cardillo TE; Rooney TP; Macias WL; de Bono S; Schlichting DE; Smolen JS
    N Engl J Med; 2016 Mar; 374(13):1243-52. PubMed ID: 27028914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
    van der Heijde D; Dougados M; Chen YC; Greenwald M; Drescher E; Klar R; Xie L; de la Torre I; Rooney TP; Witt SL; Schlichting DE; de Bono S; Emery P
    RMD Open; 2018; 4(1):e000662. PubMed ID: 29765703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.
    Tanaka Y; Atsumi T; Amano K; Harigai M; Ishii T; Kawaguchi O; Rooney TP; Akashi N; Takeuchi T
    Mod Rheumatol; 2018 Jul; 28(4):583-591. PubMed ID: 29134891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.
    Alten R; Burmester GR; Matucci-Cerinic M; Salmon JH; Östör A; Ng KJ; Gerwien J; Zaremba-Pechmann L; Brnabic AJM; Fautrel B
    Rheumatol Ther; 2023 Dec; 10(6):1575-1595. PubMed ID: 37755648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
    Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
    Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
    Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids.
    van Vollenhoven R; Helt C; Arora V; Zhong J; Correia AP; de la Torre I; Muram D
    Rheumatol Ther; 2018 Dec; 5(2):525-536. PubMed ID: 30357613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.